Abstract
Epilepsy is the most prevalent chronic neurologic condition. In developed countries, its incidence is 30–50 per 100 000 population per year and the prevalence is approximately 5–8 cases per 1 000 population. The rapid growth of health care expenditures has led to increased interest in economic evaluation of health care programs. We reviewed studies on the costs of epilepsy to assess the significance of their quantitative results, through a specific scheme of analysis. The main findings of our study are that a general consensus on cost of illness evaluation is still remote and many studies lack technical details, making difficult any useful comparison of results. New efforts should be realized to achieve a major degree of standardization in methodological processes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shorvon SD (1996) The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 37[Suppl 2]: S1-S3
Drummond M, Brandt A, Luce B, Rovira J (1993) Standardizing methodologies for economic evaluation in health care. Int J Technol Assess Health Care 9 (1): 26–36
Jefferson T, Demicheli V, Mugford M (1996) Elementary economic evaluation in health care. BMJ Publishing Group, London
Drummond MF, Stoddart GL, Torrance GW (1987) Methods for the economic evaluation of health care programmes. Oxford Medical, Oxford
Drummond M (1992) Cost-of-illness studies. A major headache? PharmacoEconomics 2(1):1–4
Mooney G (1994) Key issues in health economics. Harvester Wheatsheaf, London
Davey PJ, Leeder SR (1992) The cost of migraine. More than just a headache? PharmacoEconomics 2(1):5–7
Rice DP (1994) Cost of illness studies: Fact or fiction? Lancet 344:1519–1520
Galli R, Pani M, Gneri C, et al (1996) II costo della diagnosi e il trattamento dell’epilessia. Farmacoeconomia 2:24–29
Di Liso G, Di Ciommo V, Cutrera R et al (1996) Convulsioni febbrili ed epilessie in un ospedale pediatrico: Analisi dei costi. Boll Lega It Epil 95/96:23–26
Munari C, Tassi L, Mai R, et al (1994) Organizzazione dell’assistenza al paziente con epilessia: La terapia neurochirurgica. Boll Lega It Epil 95/96:27–32
Tinuper P (1996) I costi della terapia farmacologica dell’epilessia. Boll Lega It Epil 95/96:33–34
Australian Commonwealth Department of Human Services and Health (1995) Guidelines for the pharmaceutical industry on preparation of submissions to the PBAC. Australian Government Publishing Service, Canberra
Banks GK, Regan KJ, Beran RG (1995) The prevalence and direct costs of epilepsy in Australia. In: Cost of epilepsy. Proceedings of the 20th International Epilepsy Congress, pp 39–48
Beran RG, Banks GK (1995) Indirect costs of epilepsy in Australia. In: Cost of epilepsy. Proceedings of the 20th International Epilepsy Congress, pp 49–54
Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA (1994) Cost of epilepsy in the United States: A model based on incidence and prognosis. Epilepsia 35:1230–1243
Cockerell OC, Hart YM, Sander JWAS, Shorvon SD (1994) The cost of epilepsy in the United Kingdom: An estimation based on the results of two population-based studies. Epilepsy Res 18:249–260
Gessner U, Sagmeister M, Horisberger B (1995) The economic impact of epilepsy in Switzerland. In: Cost of epilepsy. Proceedings of the 20th International Epilepsy Congress, pp 67–74.
Ament A, Evers S (1993) Cost of illness studies in health care: A comparison of two cases. Health Policy 26:29–42
Tolpin HG, Bentkover JD (1983) Economic costs of illness: Decision making applications and practical considerations. In: Scheffler R, Rossiter L (eds) Advances in health economic and health services resources. JAI, Greenwich
Blumenschein K, Johannesson M (1996) Economic evaluation in healthcare. PharmacoEconomics 10(2):114–122
Johannesson M (1994) The concept of cost in the economic evaluation in health care. Int J Technol Assess Health Care 10 (4):675–682
Koopmanschap MA, Rutten FFH (1995) Indirect costs in economic studies: Confronting the confusion. PharmacoEconomics 4(6):446–454
Koopmanshap MA, Rutten FFH (1996) A practical guide for calculating indirect costs of disease. PharmacoEconomics 10(5):460–466
Liljas B (1998) How to calculate indirect costs in economic evaluations. PharmacoEconomics 13(1):1–7
Rice DP (1996) Estimating the cost of illness. Health economic series No.6, Public Health Service. US Government Printing Office, Washington DC